


Adaptive MR-guided stereotactic ablative body radiotherapy (MRgSABR) for pancreas cancer: dosimetric evaluation from EMERALD trial

RESULTS Between August 2022 to October 2023, 20 patients underwent MRgSABR • (Level1 n = 4, Level2 n = 8, Level3 n = 8) • One patient in Level1 did not complete the treatment course due to development of obstructive jaundice requiring stenting • Of the total of 49 fractions, 100% were successfully delivered using daily adaption Retrospective dosimetric data was available from 37 plans treatment plan produced from simulation imaging Baseline baseline plan recomputed on anatomy of the day Predicted \longrightarrow treatment plan reoptimised on the anatomy of the day Reoptimised 76% of predicted plans failed to meet OAR constraints Following daily adaption: • All reoptimised plans met mandatory OAR dose constraints • PTVHigh V(95%) was maintained across all dose levels Despite larger tumour size in Level3, mean PTVHigh coverage remained >95% Summary of key dosimetric statistics for each dose level **GTV V(BED**₁ PTV V (100%) % PTVHigh V (95%) % median (ra mean (range) mean (range) Level Predicted Reoptimised Baseline Predicted Reoptimised Predicted Re Baseline 85.05 84.24 96.75 99.67 99.17 88.32 99.78 Single-centre three-arm phase 1 non-randomised (50 Gy/5) (80-93.54) (73.2-93.5) (77.5-95) (99.5-99.6) (83.7-99) (97.5-99.9) (96.8-100) (9 safety study (ISRCTN10557832)⁶ Localised (locally advanced and inoperable) or locally 83.57 99.37 97.62 98.76 96.6 82.44 recurrent pancreatic cancer ÷ Ģ (39 Gy/3) (66.3-89.5) (66,3-87,5) (60-92.3) (96.6-99.9) (94.8-99.3) (97.8-99.7) (86.4-99.9) (86 All patients were treated with daily online adaptive MRgSABR (MRIdian Linac, ViewRay Systems Inc, OH) 67.91 72.72 94.78 96.98 86.13 99.3 77.45 3 (25 Gy/1) (66.8-85.2) (61.6-86.8) (64.9-89) (96.8-99.9) (80.4-99.3) (94.1-99.7) (71.7-90.6) (71

INTRODUCTION One in three pancreas adenocarcinoma patients die of local progression¹. SABR may be a treatment option, however target motion and critical organ at risk (OAR) proximity are major obstacles in achieving acceptable PTV coverage and severe toxicity has been reported^{2,3}. MR-guided SABR (MRgSABR) allows beamgating, real-time tracking, and daily plan adaptation based on changes in tumour or OAR, showing promise results in this setting⁴. The EMERALD trial evaluated the feasibility and safety of ultra-hypofractionation with MRgSABR in pancreatic cancer. As $BED_{10} > 70$ Gy has been associated with improved survival⁵ this dose range was investigated in the three dose levels (BED₁₀ 87.5 - 100 Gy). Each of the arms was assessed as an independent cohort. The primary endpoint of EMERALD was dose limiting toxicity (DLT). AIM We present the dosimetric impact of adaptive MRgSABR from the EMERALD trial. We also evaluated the GTV and PTV coverage within the BED 70 Gy isodose METHOD



- Induction chemotherapy was recommended but not mandatory
- Three dose levels were evaluated:
- **Level1: 50 Gy / 5#** (BED₁₀ 100 Gy)
- Level2: 39 Gy / 3# (BED₁₀ 90 Gy)
- **Level3: 25 Gy / 1#** (BED₁₀ 87.5 Gy)
- The planning objectives were:
- 98% of PTVHigh receives \geq 95% of the prescribed dose
- Minimum PTV V(100%) ≥60%
- Maximum PTV V(1 cc) \geq 125% and \leq 140%

<u>E. Moreno-Olmedo^{1,2,3}</u>; B. George ¹; S. Teoh³; R. Owens ^{1, 2}; L. Swan³, J. Good ¹, T. Maughan³, S. Mukherjee ^{1,2,3}

¹GenesisCare UK, United Kingdom;


BED₁₀: Biological Effective Dose; BED 70= 39.5Gy/5#; BED 70= 33.2 Gy/3#; BED 70Gy= 22Gy/1#.

CONCLUSIONS


In the EMERALD trial, daily adaptive MRgSABR achieved optimal PTV_High V(95%) coverage whilst maintaining all mandatory OAR dose constraints across all dose levels. This was true even in the Level3 (25 Gy, single fraction) despite larger average tumour size and extreme hypofractionation.

EMERALD clinical outcomes will be reported shortly.

²Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; ³Oxford University Hospitals NHS Foundation Trust



9 ₁₀ 70)%	PTV V(BED ₁₀ 70)%		GTV (cc)		PTV (cc)	
range)	median (range)		mean (range)		mean (range)	
eoptimised	Predicted	Reoptimised	Baseline	Adapted	Baseline	Adapted
99.3	94.35	94.8	31.91	35.64	70.15	76.33
(96.7-100)	(88.8-99.5)	(88.35-99)	(16-54.1)	(18.5-64.5)	(41.7-117.5)	(45.2-134.2)
95.2	91.6	88.8	30.67	34.12	73.08	80.21
86.5-99.9)	(77.5-95.7)	(78.2-96.1)	(14.6-115.3)	(18.2-120.3)	(39.7-210.5)	(70.3-205.6)
84	78.13	79	42.19	48.70	89.16	83.70
71.1-94.5)	(72.7-81.8)	(72.5-85.5)	(8.63-79.1)	(10.7-93.6)	(21.9-154.7)	(11.5-170.8)




ACKNOWLEDGEMENTS

We thank patients and their families involved in the study, as well as all members of the professional team who participated.

Funding provided by

- Oxford University-GenesisCare Collaboration Fund
- John Black Charitable Foundation
- Oxford Institute for Radiation Oncology, University of Oxford.





Representative Level3 (25 Gy, single fraction) plan. MIM® 7.2.8. 1 Planning System

REFERENCES

. Iacobuzio-Donahue CA, Fu B et al. J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188

Salama JK, Hasselle MD, Chmura SJ, et al.. Cancer 2012;118:2962–70. https://doi.org/10.1002/cncr.26611.

. Palma DA, Olson R, Harrow S, et al.. Lancet 2019. https://doi.org/10.1016/S0140-6736(18)32487-5.

4. Chuong MD, Radiother Oncol. 2024 Feb;191:110064. doi: 10.1016/j.radonc.2023.110064. . Rudra S,. Cancer Med. 2019 May;8(5):2123-2132. doi: 10.1002/cam4.2100.

6. Teoh S et al. BMJ Open. 2023 Sep 14;13(9):e068906. doi: 10.1136/bmjopen-2022-068906.

O Elena Moreno-Olmedo, MD. GenesisCare Oxford, UK ➢ elena.moreno2@genesiscare.co.uk X @elenmol2